Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baoshentongluo Xizhuo prescription is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Beijing Hospital of Traditional Chinese Medicine, Capital Medical University. It is utilized as part of a staged 'Yishentongluo' therapeutic strategy for the treatment of diabetic kidney disease (DKD). The 'Xizhuo' component of the therapy is specifically designed to 'clear turbidity,' a TCM principle aimed at managing metabolic waste and slowing the progression of renal dysfunction. In clinical studies, it is evaluated as an adjunct to standard Western medical treatments in adults with chronic kidney disease (CKD stages 1–4) to reduce proteinuria and preserve kidney function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baoshentongluo Xizhuo prescription.